Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of PB-119 in Subjects With Renal Insufficiency
NCT05328843Phase 1Unknown
- Sponsor
- PegBio
- Start
- May 2022
- Primary completion
- Oct 2022
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of visepegenatide in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by PegBio. Primary endpoints: Area Under the Concentration-Time Curve From Time Zero to Infinity, Area Under the Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration and 1 more. Status: unknown.
02
Drugs
visepegenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05328843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05328843.